Voena C - Search Results

1

Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL.

Vitale C, Griggio V, Riganti C, Todaro M, Kopecka J, Jones R, Salvetti C, Boccellato E, Perutelli F, Voena C, Godio L, Boccadoro M, Coscia M. Vitale C, et al. Among authors: voena c. Cancers (Basel). 2021 Jun 9;13(12):2883. doi: 10.3390/cancers13122883. Cancers (Basel). 2021. PMID: 34207596 Free PMC article.

2

The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma.

Corradini P, Ferrero D, Voena C, Ladetto M, Boccadoro M, Pileri A. Corradini P, et al. Among authors: voena c. Br J Haematol. 1993 Apr;83(4):672-3. doi: 10.1111/j.1365-2141.1993.tb04711.x. Br J Haematol. 1993. PMID: 7686038 No abstract available.

3

High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.

Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A. Corradini P, et al. Among authors: voena c. Blood. 1995 Mar 15;85(6):1596-602. Blood. 1995. PMID: 7888677 Free article.

4

Detection of circulating tumor cells in multiple myeloma by a PCR-based method.

Corradini P, Voena C, Omedé P, Astolfi M, Boccadoro M, Dalla-Favera R, Pileri A. Corradini P, et al. Among authors: voena c. Leukemia. 1993 Nov;7(11):1879-82. Leukemia. 1993. PMID: 8231256

5

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.

Corradini P, Boccadoro M, Voena C, Pileri A. Corradini P, et al. Among authors: voena c. J Exp Med. 1993 Sep 1;178(3):1091-6. doi: 10.1084/jem.178.3.1091. J Exp Med. 1993. PMID: 8350048 Free PMC article.

6

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A. Corradini P, et al. Among authors: voena c. Blood. 1993 May 15;81(10):2708-13. Blood. 1993. PMID: 8490179 Free article.

7

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G. Boccalatte FE, et al. Among authors: voena c. Blood. 2009 Mar 19;113(12):2776-90. doi: 10.1182/blood-2008-06-161018. Epub 2008 Oct 9. Blood. 2009. PMID: 18845790 Free PMC article.

8

RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.

Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Doublier S, et al. Among authors: voena c. Mol Cancer Res. 2008 Oct;6(10):1607-20. doi: 10.1158/1541-7786.MCR-08-0251. Mol Cancer Res. 2008. PMID: 18922976

9

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. Riganti C, et al. Among authors: voena c. Mol Pharm. 2011 Jun 6;8(3):683-700. doi: 10.1021/mp2001389. Epub 2011 May 5. Mol Pharm. 2011. PMID: 21491921

10

Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.

Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, Ghigo D. Polimeni M, et al. Among authors: voena c. Biochem J. 2011 Oct 1;439(1):141-9. doi: 10.1042/BJ20102016. Biochem J. 2011. PMID: 21679161

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters